Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (not Talpher, Inc.) for the reporting period of August 1, 2012. The company is a Delaware corporation headquartered in Redwood City, California, focused on pharmaceutical development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements.
Material Changes
The material event reported is the issuance of two patents by the U.S. Patent and Trademark Office:
- Patent Number 8,226,978: "Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain."
- Patent Number 8,231,900: "Small-Volume Oral Transmucosal Dosage Forms."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the general context of patent issuance. The primary purpose is to disclose the intellectual property milestone.
Investor Verification Checklist
- Verify the commercial viability and market potential of the newly granted patents (Nos. 8,226,978 and 8,231,900).
- Confirm the status of the Company's clinical trials related to the sufentanil dosage forms.
- Review the attached press release (Exhibit 99.1) for additional details on the patent scope.
- Check subsequent filings for any financial impact or strategic shifts resulting from these patents.